Spinal Muscular Atrophy: Disease Mechanisms and Therapy provides the latest information on a condition that is characterized by motoneuron loss and muscle atrophy, and is the leading genetic cause of infant mortality. Since the identification of the gene responsible for SMA in 1995, there have been important advances in the basic understanding of disease mechanisms, and in therapeutic development.
This book provides a comprehensive accounting of recent advances in basic and clinical research that covers SMA clinical features and standards of care, multifaceted aspects of SMN protein functions and SMA disease pathology, various animal models, and biomarkers, as well as current therapeutic development.
This title is ideal for graduate students/postdocs and principal investigators who are already in the SMA field and need to keep updated on recent findings and approaches, and for those who are new to, or would like to join, the field. Likewise, users will find an excellent source of reading for biotech/pharma scientists, clinical researchers, and practitioners, regulators, and patients and their advocacy organizations. Furthermore, this book is a handy reference for researchers and clinicians who may want to apply the research strategies and therapeutic approaches in SMA to other rare diseases.
- Provides comprehensive, up-to-date reviews by leading investigators on diverse topics of SMA, including clinical features and patient care, SMN genetics and protein functions, animal models, disease pathology and mechanisms, biomarkers, current therapeutic development, and the role of non-profit organizations in therapeutic development
- Written to bridge multiple disciplines and promote better communications among basic scientists, clinical researchers, and health care providers on the latest developments in SMA
- Includes outstanding questions and perspectives for future investigations and key references for additional detailed study
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
ISBN-13
978-0-12-803686-0 (9780128036860)
Schweitzer Klassifikation
Section I. Clinical Features and Diagnosis of SMA1. Spinal Muscular Atrophy: 125 Years Later and on the Verge of a Cure2. Developmental Aspects and Pathological Findings in Spinal Muscular Atrophy3. Standard of Care for Spinal Muscular Atrophy4. Strategy for the Molecular Testing of Spinal Muscular Atrophy
Section II. Cellular and Molecular Mechanisms of the Disease5. Transcriptional and Splicing Regulation of Spinal Muscular Atrophy Genes6. The Function of Survival Motor Neuron Complex and Its Role in Spinal Muscular Atrophy Pathogenesis7. RNA-Processing Dysfunction in Spinal Muscular Atrophy8. Axonal and Neuromuscular Junction Pathology in Spinal Muscular Atrophy9. Motor Circuit Dysfunction in Spinal Muscular Atrophy10. Contributions of Different Cell Types to Spinal Muscular Atrophy Pathogenesis11. Temporal Requirements for the Survival Motor Neuron Protein12. Spinal Muscular Atrophy Disease Modifiers
Section III. Cell and Animal SMA Models13. Cell Culture Models of Spinal Muscular Atrophy14. Nonmammalian Animal Models of Spinal Muscular Atrophy15. Mammalian Models of Spinal Muscular Atrophy
Section IV. Therapeutic Development16. Spinal Muscular Atrophy Therapeutics Development17. Small Molecule Approaches to Upregulate SMN Expression From the SMN2 Locus18. Antisense-Oligonucleotide Modulation of SMN2 Pre-mRNA Splicing19. Gene Transfer in Spinal Muscular Atrophy20. Neuroprotection As a Therapeutic Approach for Spinal Muscular Atrophy21. Skeletal Muscle in Spinal Muscular Atrophy As an Opportunity for Therapeutic Intervention22. Addressing Cell Therapy for Spinal Muscular Atrophy: Open Issues and Future Perspectives
Section V. Clinical Research23. Spinal Muscular Atrophy Motor Functional Scales and Measures of Pulmonary Function24. Development and Testing of Biomarkers in Spinal Muscular Atrophy25. Natural History of Spinal Muscular Atrophy26. Spinal Muscular Atrophy Clinical Trials: Lessons Learned